You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
“股神”巴菲特減持藥業股 增持雪佛龍
格隆匯11月16日丨美國“股神”巴菲特投資旗艦Berkshire Hathaway(伯克希爾哈撒韋公司)上季減持Visa與萬事達這兩間支付營運商,以及艾伯維(ABBV.US)與Bristol Myers-Squibb這兩間藥廠股份。 根據巴郡週一披露的上季持倉變化,該公司削減艾伯維持股30%、Bristol Myers-Squibb持股16%,以及不再持有默克(MRK.SU)藥廠;Visa與萬事達的減持比例分別爲4.3%與6%。 該公司未有全面看淡藥品股,上季增持Royalty Pharma(RPRX.US),也保持Teva(TEVA.US)股份數量不變。該公司上季首度買入Floor & Decor(FND.US),也增加雪佛龍(CVX.US)24%持股至市值達29.1億美元。 巴郡在第三季股票組合錄得淨減少,是連續第四個季度錄得淨減少。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account